2 Result Science
2021年6月13日Register here: http://gg.gg/uywu0
Odisha CHSE Science Results 2020: The official result website of Council for Higher Secondary Education, or CHSE, - orissaresults.nic.in will host the CHSE +2 result Odisha board. Odisha CHSE +2 Science Results are expected today at 11 am at the official website, the students will be able to check updates at 11 am on official website. Students can get marks list when the. Odisha CHSE +2 Science Result 2020: Here’s list of websites to check 12th scores The Council of Higher Education (CHSE) Odisha will declare the class 12th Science stream exam results today at.
Check Odisha +2 Science Result 2020 Declared: Putting an end to the long wait, CHSE Odisha has officially announced +2 Results 2020 for Science stream students. Odisha +2 Results 2020 were declared in a formal declaration ceremony which was graced by State Education Minister Samir Dash. Mr Das formally declared the Odisha Class 12 Science Results 2020 and also announced the key highlights and statistics for the results. Following the formal declaration, students can now log onto official website i.e. chseodisha.nic.in and orissaresults.nic.in to check and access their CHSE Odisha +2 Science Scorecard online. Alternatively, the scorecard can also be accessed directly via the result checking link provided below:
Keep refreshing this page for live updates on CHSE Odisha +2 Science Result 2020!Nayagarh Emerges as Top Performing District
According to the information provided by the Council of Higher Secondary Education, Odisha (CHSE, Odisha), Nayagarh district has emerged as the best performing district in the state for Science stream results. Nayagarh district has reported an overall pass percentage of 86.51%. On the other hand, Jharsuguda with an overall success ratio of 40.71% is the worst performing district.
*Best Performing District: Nayagarh (86.51%)
*Worst Performing District: Jharsuguda (40.71%)
*Number of Schools with 100% Pass Percentage: 20
*Number of Schools with 0% Pass Percentage: 15CHSE Odisha Science Result Declared - Key Highlights and Statistics
According to the details shared by the CHSE Odisha, a total of 97,546 students had appeared for the +2 Science Stream Exam and were expecting their result to be declared today. Of this number, 68,374 students have cleared the exam with flying colours taking the overall pass percentage to 70.21%. Other statistical highlights for CHSE Odisha +2 Science Results 2020 are given below:
*Number of STudents Appeared for Science Stream: 97,546
*Total Number of Passed Students for Science Stream: 68,374
*Overall Pass Percentage: 70.21%
*Number of Male Students Passed: 38,301
*Number of Girl Students Passed: 30,073Division-wise Performance of Students
Along with sharing the overall pass percentage for Odisha + Science Result 2020, the Council has also announced the division-wise performance of the students in the recently announced results. According to reports, for Odisha 12th Science Results, first division has been secured by 25,339, second division has been secured by 24,121, while third division has been awarded to 18,268.
*Students passed in 1st Division: 25,339
*Students passed in 2nd Division: 24,121
*Students passed in 3rd Division: 18,26870.21% Students Pass, Pass Percentage Falls Marginally
In the formal declaration ceremony held today, the State Education Minister Samir Dash officially announced the CHSE Odisha +2 Science Stream Results 2020. During the declaration function, he also announced that the overall pass percentage for Odisha 12th Science Result 2020 has been reported at 70.21%. This means the overall success ratio has fallen by small margin as last year the pass percentage was 72%.
Official Website Crashes, Students Unable to Check Results
As per the latest update, CHSE Odisha has activated the link to check Odisha 12th Result 2020 for Science stream students on the result checking portal i.e. orissaresults.nic.in. However, the official link is either not activated or has become inaccessible due to heavy traffic on the website. Many students who have tried to check their Odisha Class 12 Results 2020 have reported that the official website is inaccessible. The problem has been notified to the board and will soon be fixed. Until then, students are advised to stay tuned to this page for live updates on CHSE Odisha +2 Results 2020.Last Year’s Performance
As students wait for the declaration of CHSE Odisha 12th Science Result 2020, it is natural for them to be excited and anxious at the same time. However, one way of clam down your nerves would be by looking at the performance of students in the Odisha +2 Science Result 2020 from last year and basing your expectations accordingly. To help students get an idea about how did students perform in CHSE Odisha results of previous, some key statistical highlights are listed below:Plus 2 Science Result 2020 Odisha
*Overall Pass Percentage: 78.76
*Pass Percentage among Girls: 81.98%
*Pass Percentage among Boys:School Education Minister To Declare Result at 12:30 PM
The tweet also confirmed that the formal declaration of CHSE Odisha Plus Two Results 2020 will be done by the School & Mass Education Minister Samir Ranjan Dash. Like every year, after the formal declaration, the Odisha +2 Science Results 2020 will be made available to the students online via official website i.e. orissaresults.nic.in. To be among the first students to be able to check their Odisha 12th Science Results, students are advised to click on the below-given link and register for alerts. On the day of Result, the link will be activated first and Odisha 12th Science Result 2020 will be made accessible to the students first here.Odisha +2 Results Prepared As per Alternative Assessment Scheme
Odisha Class 12 Board Exams 2020 for +2 Students was deeply impacted by the COVID-19 outbreak in the month of March. The Class 12 Board Exams was originally scheduled to be held from 6th to 28th March 2020; however, all exams scheduled after 23rd March i.e. announcement of national lockdown, were initially postponed and later on cancelled in the light of Coronavirus pandemic threat. For the assessment of students for the cancelled papers, the Council of Higher Secondary Education has adopted an alternative assessment policy, similar to the one used by CBSE Board. As per the new policy, the board will use average marks formula to award marks to the students.Re-Exam for Unsatisfied Students
Similar to CBSE board, the CHSE Odisha has also decided to hold re-exam for students who are not happy with the score awarded to them on the basis of the internal assessment policy on average marks formula. Such students will be able to reappear for the Class 12 Board Exam at a later day, when the board feels it is feasible to hold the Class 12 Board Exams. However, if a candidate appears for the optional examination, the marks obtained will be treated as final.AB SCIENCE COMMUNICATES RESULTS FROM PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER’S DISEASEParis, December 18, 2020, 8.30am CETAB Science SA (NYSE Euronext – FR0010557264 – AB) today communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease, together with details on the mode of action of masitinib in Alzheimer’s disease. The presentation is available on the company’s website and is available here.Highlights of this presentation are:The mode of action of masitinib in Alzheimer’s disease (AD) is based on four targets, which may have a synergistic effect:
*Modulation of microglia: Microglia are involved in neuroinflammartoy processes associated with AD and masitinib modulates microglia activity through inhibition of the CSFR-1 kinase.
*Protection of synapses: Synapses are altered in AD and masitinib has been shown to promote recovery of synaptic markers in a mouse model of AD.
*Inhibition of the tau protein: The tau protein aggregates in the physiopathology of AD. Masitinib inhibits the FYN kinase, a kinase that mediates tau phosphorylation. Masitinib has also been shown to prevent the accumulation of amyloid fibrils in the hippocampus in a mouse model of AD.
*Control of mast cell activity: Mice depleted of mast cells (MCs) do not develop symptoms of AD. Masitinib blocks MC activity through inhibition of the c-Kit, LYN, and FYN kinases. In addition, beta-amyloid plaques activate MCs, and masitinib treatment of transgenic AD mice has been shown to protect against cognition impairment.The following preclinical data are presented. Experiments in a transgenic mouse model of AD that were carried out by the ICM Brain Institute in Paris, demonstrated that masitinib could:
*Completely restore cognitive impairment in the Morris Water Maze experiment.
*Completely restore the ability to perform navigation strategy in the Morris Water Maze experiment.
*Exerts a neuroprotective effect against synaptic loss through inhibition of MCs.The masitinib clinical development program in Alzheimer’s disease is comprised of one proof of concept study (AB04024) [Piette, 2011] and a phase 2B/3 study (AB09004).Masitinib is positioned in patients with mild and moderate dementia, with MMSE Score (Mini Mental State Examination) ranging from 12 to 25, which is a different positioning from other compounds.There are currently four drugs used in the treatment of mild and moderate AD (donepezil, rivastigmine, galantamine and memantine) that were approved about 20 years ago. Masitinib was evaluated in add-on to this standard of care.Study AB09004 was an international, randomized, placebo-controlled, phase 2B/3 study evaluating different doses of masitinib as a treatment of patients with confirmed mild to moderate Alzheimer’s disease. This study compared the efficacy and safety of masitinib relative to placebo after 24 weeks of treatment when administered as an add-on therapy to cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or Memantine.Study AB09004 was comprised of two independent sub-studies testing two distinct dosing regimens; masitinib 4.5 mg/kg/day versus its own placebo control (n=358, randomization 1:1), and masitinib 6.0 mg/kg/day titrated dose versus its own placebo control (n=277, randomization 2:1).The study was to be considered successful if a significant improvement was reached on either ADAS-Cog or ADCS-ADL at a 2.5% level of statistical significance.
Baseline characteristics were balanced. Study AB9004 results were the following:
*The study met its primary analysis, demonstrating a statistically significant reduction in cognitive impairment based on ADAS-Cog (p=0.0003). Treatment-effect with respect to the control arm (i.e., between group difference of least squares mean (LS Mean) and associated standard error (SE) in ADAS-Cog was -2.15 (0.59).
*ADAS-Cog sensitivity analysis based on the jump to reference imputation method remained positive (p=0.0016), demonstrating a robust treatment statistical effect.
*The study demonstrated a statistically significant improvement on daily activity based on ADCS-ADL (p=0.0381). The difference of LS Mean (SE) in ADCS-ADL was 1.82 (0.87).
*ADCS-ADL sensitivity analysis based on the jump to reference imputation method showed a numerical advantage close to statistical significance (p=0.051) in favor of masitinib.
*The study demonstrated a 71% improvement on Clinician’s Interview-Based Impression of Change (CIBIC) for masitinib as compared with placebo; a result that was statistically significant (p=0.040).
*The study showed a numerical advantage (not statistically significant) in favor of masitinib on the secondary enpoints of MMSE, CDR, and NPI.
*No further significant treatment-effect was observed either on ADAS-Cog or ADCS-ADL for the high-dose masitinib sub-study (titration up to 6.0 mg/kg/day). This result possibly originated from an improvement under placebo, conceivably influenced by a low number of patients enrolled in the placebo titration arm (n<100). There was no higher efficacy with the masitinib 6.0 mg/kg/day titrated dose versus the misitinib 4.5 mg/kg/day dose. As a result, it could be concluded that the effective dose in Alzheimer’s disease for masitinib is 4.5 mg/kg/day.
*As a post-hoc sensitivity analysis, in order to assess the impact of the divergent placebo effect, masitinib 4.5 mg/kg/day was compared with the pooled placebo arms and ADAS-Cog analysis remained significant (p=0.0004).
*There were significantly (log-rank p-value 0.0403) fewer patients reaching severe dementia stage (MMSE<10) and a significant decrease (Hazard ratio 1.19, p= 0.0276) in time to severe dementia with masitinib 4.5 mg/kg/day compared with the pooled placebo arms.
*The safety of masitinib was consistent with its known tolerability profile.A new patent was filed based on results from study AB09004, which would permit AB Science to retain exclusive rights on the use of masitinib in Alzheimer’s disease until 2041.Bruno Dubois (MD, PhD), Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital at Paris in France and coordinating investigator of the study said: “Study AB09004 was a well-designed phase 2b/3 as it compared masitinib on top of standard of care treatment versus the standard of care. These data are very encouraging and may provide new hope for patients with Alzheimer’s disease”.Philip Scheltens (MD, PhD), Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam said: “Results from study AB09004 bring a novel mechanism of action, which is very interesting considering the need for effective treatment in AD. The positive results from this study provide a robust basis to initiate a phase 3 confirmatory study”.Jeffrey L. Cummings (M.D), Director of the Chamber-Grundy Center for Transformative Neuroscience at UNLV in Las Vegas said: “The data from this study are promising and support the use of the dose 4.5 mg /kg/day of masitinib for the future confirmatory study. Based on the mechanism of action of masitinib targeting the innate immune system via mast cells and microglia, it should be possible to investigate the correlations between clinical endpoints and biomarkers of neuro-inflammation and neurodegeneration in the next study”.
KOL BiographiesThe following key opinion leaders participated in the webcast:Bruno Dubois
Bruno Dubois is currently Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital at Paris, University Pierre et Marie Curie Paris VI. He is Director of the Behavioural Neurology Department and of the Dementia Research Center at the Hospital. He is also Director of the Research Unit Inserm U-610 of the ICM (Institut du Cerveau et de la Moelle Epinière) of the Hospital. He is coordinator of the National Reference Center on Rare Dementias and of the National Reference Center for young-onset Alzheimer patients. He is President of the Scientific Committee of France-Alzheimer and of IFRAD (International Fund Raising for Alzheimer’s disease), consultant for the Human Frontier Program and Expert of the French Agency of Drugs. He is a member of the European Alzheimer Disease Consortium (EADC). He has published on anatomical and biochemical studies on the central cholinergic systems in rodents and humans; on cognitive neuropharmacology; and on neuropsychology in patients with dementia, with special reference to memory and executive functions. He recently organized an Expert Consensus on the new criteria for Alzheimer’s disease and a Task Force on the new criteria for Parkinson’s disease dementia. He is principal or co-investigator of a number of research programs focusing on AD, prodromal AD and dementia in Parkinson’s disease.Philip Scheltens
Philip Scheltens, MD, PhD is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam, as well as Honorary Professor of Neurology at University College London. From 2011-2015, he was the scientific director of the Dutch Pearlstring Institute (PSI). In 2013, he was appointed vice-chair of the board of the Dutch “Deltaplan Dementie”. Since 2015, he has been a member of the board of the Royal Academy of Sciences and Art. His main clinical and research interests are dementia in the broadest sense, from basic research to care and translational research. He is active in the field of biomarkers and clinical trials and has been the (inter) national PI for many studies, including Phase I–III multicentre clinical trials. He is founder of, and has directed since 2000, the VUmc Alzheimer Center in The Netherlands, and during this period, he has produced over 50 PhD theses. He also founded the Alzheimer Research Center, a center dedicated to and specialised in Alzheimer clinical trials, where he is now a scientific adviser and member of the Board of Trustees. Dr. Scheltens is an active member of several societies, including the Dutch Society for Neurology, the AAN, the Alzheimer Imaging Consortium, the ISTAART Consortium, and the ECNP. He has been instrumental in organising several national and international conferences, including the Imaging Symposium attached to AAIC. He is member of the management board of the dementia panel of the EAN. He is co-editor-in-chief of Alzheimer’s Research & Therapy and acts as an ad hoc reviewer of scientific articles for all of the major journals. He has authored >730 peer reviewed papers and >50 book chapters. His current Hirsch factor is 117 (Google Scholar).Jeffrey L. Cummings
Jeffrey L. Cummings, M.D., is Director of the Chamber-Grundy Center for Transformative Neuroscience at UNLV in Las Vegas. Dr. Cummings is principal investigator/ director of the National Institutes of Health/National Institute of General Medical Sciences-funded Center for Neurodegeneration and Translational Neuroscience. Dr. Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the National Alzheimer’s Association (2008) and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. He was featured in Gentlemen’s Quarterly (June 2009) as a “Rockstar of Science.” Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases and the interface of neuroscience and society. Dr. Cummings was formerly professor of neurology and psychiatry at the University of California, Los Angeles (UCLA), director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA and director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association. Dr. Cu
https://diarynote.indered.space
Odisha CHSE Science Results 2020: The official result website of Council for Higher Secondary Education, or CHSE, - orissaresults.nic.in will host the CHSE +2 result Odisha board. Odisha CHSE +2 Science Results are expected today at 11 am at the official website, the students will be able to check updates at 11 am on official website. Students can get marks list when the. Odisha CHSE +2 Science Result 2020: Here’s list of websites to check 12th scores The Council of Higher Education (CHSE) Odisha will declare the class 12th Science stream exam results today at.
Check Odisha +2 Science Result 2020 Declared: Putting an end to the long wait, CHSE Odisha has officially announced +2 Results 2020 for Science stream students. Odisha +2 Results 2020 were declared in a formal declaration ceremony which was graced by State Education Minister Samir Dash. Mr Das formally declared the Odisha Class 12 Science Results 2020 and also announced the key highlights and statistics for the results. Following the formal declaration, students can now log onto official website i.e. chseodisha.nic.in and orissaresults.nic.in to check and access their CHSE Odisha +2 Science Scorecard online. Alternatively, the scorecard can also be accessed directly via the result checking link provided below:
Keep refreshing this page for live updates on CHSE Odisha +2 Science Result 2020!Nayagarh Emerges as Top Performing District
According to the information provided by the Council of Higher Secondary Education, Odisha (CHSE, Odisha), Nayagarh district has emerged as the best performing district in the state for Science stream results. Nayagarh district has reported an overall pass percentage of 86.51%. On the other hand, Jharsuguda with an overall success ratio of 40.71% is the worst performing district.
*Best Performing District: Nayagarh (86.51%)
*Worst Performing District: Jharsuguda (40.71%)
*Number of Schools with 100% Pass Percentage: 20
*Number of Schools with 0% Pass Percentage: 15CHSE Odisha Science Result Declared - Key Highlights and Statistics
According to the details shared by the CHSE Odisha, a total of 97,546 students had appeared for the +2 Science Stream Exam and were expecting their result to be declared today. Of this number, 68,374 students have cleared the exam with flying colours taking the overall pass percentage to 70.21%. Other statistical highlights for CHSE Odisha +2 Science Results 2020 are given below:
*Number of STudents Appeared for Science Stream: 97,546
*Total Number of Passed Students for Science Stream: 68,374
*Overall Pass Percentage: 70.21%
*Number of Male Students Passed: 38,301
*Number of Girl Students Passed: 30,073Division-wise Performance of Students
Along with sharing the overall pass percentage for Odisha + Science Result 2020, the Council has also announced the division-wise performance of the students in the recently announced results. According to reports, for Odisha 12th Science Results, first division has been secured by 25,339, second division has been secured by 24,121, while third division has been awarded to 18,268.
*Students passed in 1st Division: 25,339
*Students passed in 2nd Division: 24,121
*Students passed in 3rd Division: 18,26870.21% Students Pass, Pass Percentage Falls Marginally
In the formal declaration ceremony held today, the State Education Minister Samir Dash officially announced the CHSE Odisha +2 Science Stream Results 2020. During the declaration function, he also announced that the overall pass percentage for Odisha 12th Science Result 2020 has been reported at 70.21%. This means the overall success ratio has fallen by small margin as last year the pass percentage was 72%.
Official Website Crashes, Students Unable to Check Results
As per the latest update, CHSE Odisha has activated the link to check Odisha 12th Result 2020 for Science stream students on the result checking portal i.e. orissaresults.nic.in. However, the official link is either not activated or has become inaccessible due to heavy traffic on the website. Many students who have tried to check their Odisha Class 12 Results 2020 have reported that the official website is inaccessible. The problem has been notified to the board and will soon be fixed. Until then, students are advised to stay tuned to this page for live updates on CHSE Odisha +2 Results 2020.Last Year’s Performance
As students wait for the declaration of CHSE Odisha 12th Science Result 2020, it is natural for them to be excited and anxious at the same time. However, one way of clam down your nerves would be by looking at the performance of students in the Odisha +2 Science Result 2020 from last year and basing your expectations accordingly. To help students get an idea about how did students perform in CHSE Odisha results of previous, some key statistical highlights are listed below:Plus 2 Science Result 2020 Odisha
*Overall Pass Percentage: 78.76
*Pass Percentage among Girls: 81.98%
*Pass Percentage among Boys:School Education Minister To Declare Result at 12:30 PM
The tweet also confirmed that the formal declaration of CHSE Odisha Plus Two Results 2020 will be done by the School & Mass Education Minister Samir Ranjan Dash. Like every year, after the formal declaration, the Odisha +2 Science Results 2020 will be made available to the students online via official website i.e. orissaresults.nic.in. To be among the first students to be able to check their Odisha 12th Science Results, students are advised to click on the below-given link and register for alerts. On the day of Result, the link will be activated first and Odisha 12th Science Result 2020 will be made accessible to the students first here.Odisha +2 Results Prepared As per Alternative Assessment Scheme
Odisha Class 12 Board Exams 2020 for +2 Students was deeply impacted by the COVID-19 outbreak in the month of March. The Class 12 Board Exams was originally scheduled to be held from 6th to 28th March 2020; however, all exams scheduled after 23rd March i.e. announcement of national lockdown, were initially postponed and later on cancelled in the light of Coronavirus pandemic threat. For the assessment of students for the cancelled papers, the Council of Higher Secondary Education has adopted an alternative assessment policy, similar to the one used by CBSE Board. As per the new policy, the board will use average marks formula to award marks to the students.Re-Exam for Unsatisfied Students
Similar to CBSE board, the CHSE Odisha has also decided to hold re-exam for students who are not happy with the score awarded to them on the basis of the internal assessment policy on average marks formula. Such students will be able to reappear for the Class 12 Board Exam at a later day, when the board feels it is feasible to hold the Class 12 Board Exams. However, if a candidate appears for the optional examination, the marks obtained will be treated as final.AB SCIENCE COMMUNICATES RESULTS FROM PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER’S DISEASEParis, December 18, 2020, 8.30am CETAB Science SA (NYSE Euronext – FR0010557264 – AB) today communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease, together with details on the mode of action of masitinib in Alzheimer’s disease. The presentation is available on the company’s website and is available here.Highlights of this presentation are:The mode of action of masitinib in Alzheimer’s disease (AD) is based on four targets, which may have a synergistic effect:
*Modulation of microglia: Microglia are involved in neuroinflammartoy processes associated with AD and masitinib modulates microglia activity through inhibition of the CSFR-1 kinase.
*Protection of synapses: Synapses are altered in AD and masitinib has been shown to promote recovery of synaptic markers in a mouse model of AD.
*Inhibition of the tau protein: The tau protein aggregates in the physiopathology of AD. Masitinib inhibits the FYN kinase, a kinase that mediates tau phosphorylation. Masitinib has also been shown to prevent the accumulation of amyloid fibrils in the hippocampus in a mouse model of AD.
*Control of mast cell activity: Mice depleted of mast cells (MCs) do not develop symptoms of AD. Masitinib blocks MC activity through inhibition of the c-Kit, LYN, and FYN kinases. In addition, beta-amyloid plaques activate MCs, and masitinib treatment of transgenic AD mice has been shown to protect against cognition impairment.The following preclinical data are presented. Experiments in a transgenic mouse model of AD that were carried out by the ICM Brain Institute in Paris, demonstrated that masitinib could:
*Completely restore cognitive impairment in the Morris Water Maze experiment.
*Completely restore the ability to perform navigation strategy in the Morris Water Maze experiment.
*Exerts a neuroprotective effect against synaptic loss through inhibition of MCs.The masitinib clinical development program in Alzheimer’s disease is comprised of one proof of concept study (AB04024) [Piette, 2011] and a phase 2B/3 study (AB09004).Masitinib is positioned in patients with mild and moderate dementia, with MMSE Score (Mini Mental State Examination) ranging from 12 to 25, which is a different positioning from other compounds.There are currently four drugs used in the treatment of mild and moderate AD (donepezil, rivastigmine, galantamine and memantine) that were approved about 20 years ago. Masitinib was evaluated in add-on to this standard of care.Study AB09004 was an international, randomized, placebo-controlled, phase 2B/3 study evaluating different doses of masitinib as a treatment of patients with confirmed mild to moderate Alzheimer’s disease. This study compared the efficacy and safety of masitinib relative to placebo after 24 weeks of treatment when administered as an add-on therapy to cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or Memantine.Study AB09004 was comprised of two independent sub-studies testing two distinct dosing regimens; masitinib 4.5 mg/kg/day versus its own placebo control (n=358, randomization 1:1), and masitinib 6.0 mg/kg/day titrated dose versus its own placebo control (n=277, randomization 2:1).The study was to be considered successful if a significant improvement was reached on either ADAS-Cog or ADCS-ADL at a 2.5% level of statistical significance.
Baseline characteristics were balanced. Study AB9004 results were the following:
*The study met its primary analysis, demonstrating a statistically significant reduction in cognitive impairment based on ADAS-Cog (p=0.0003). Treatment-effect with respect to the control arm (i.e., between group difference of least squares mean (LS Mean) and associated standard error (SE) in ADAS-Cog was -2.15 (0.59).
*ADAS-Cog sensitivity analysis based on the jump to reference imputation method remained positive (p=0.0016), demonstrating a robust treatment statistical effect.
*The study demonstrated a statistically significant improvement on daily activity based on ADCS-ADL (p=0.0381). The difference of LS Mean (SE) in ADCS-ADL was 1.82 (0.87).
*ADCS-ADL sensitivity analysis based on the jump to reference imputation method showed a numerical advantage close to statistical significance (p=0.051) in favor of masitinib.
*The study demonstrated a 71% improvement on Clinician’s Interview-Based Impression of Change (CIBIC) for masitinib as compared with placebo; a result that was statistically significant (p=0.040).
*The study showed a numerical advantage (not statistically significant) in favor of masitinib on the secondary enpoints of MMSE, CDR, and NPI.
*No further significant treatment-effect was observed either on ADAS-Cog or ADCS-ADL for the high-dose masitinib sub-study (titration up to 6.0 mg/kg/day). This result possibly originated from an improvement under placebo, conceivably influenced by a low number of patients enrolled in the placebo titration arm (n<100). There was no higher efficacy with the masitinib 6.0 mg/kg/day titrated dose versus the misitinib 4.5 mg/kg/day dose. As a result, it could be concluded that the effective dose in Alzheimer’s disease for masitinib is 4.5 mg/kg/day.
*As a post-hoc sensitivity analysis, in order to assess the impact of the divergent placebo effect, masitinib 4.5 mg/kg/day was compared with the pooled placebo arms and ADAS-Cog analysis remained significant (p=0.0004).
*There were significantly (log-rank p-value 0.0403) fewer patients reaching severe dementia stage (MMSE<10) and a significant decrease (Hazard ratio 1.19, p= 0.0276) in time to severe dementia with masitinib 4.5 mg/kg/day compared with the pooled placebo arms.
*The safety of masitinib was consistent with its known tolerability profile.A new patent was filed based on results from study AB09004, which would permit AB Science to retain exclusive rights on the use of masitinib in Alzheimer’s disease until 2041.Bruno Dubois (MD, PhD), Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital at Paris in France and coordinating investigator of the study said: “Study AB09004 was a well-designed phase 2b/3 as it compared masitinib on top of standard of care treatment versus the standard of care. These data are very encouraging and may provide new hope for patients with Alzheimer’s disease”.Philip Scheltens (MD, PhD), Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam said: “Results from study AB09004 bring a novel mechanism of action, which is very interesting considering the need for effective treatment in AD. The positive results from this study provide a robust basis to initiate a phase 3 confirmatory study”.Jeffrey L. Cummings (M.D), Director of the Chamber-Grundy Center for Transformative Neuroscience at UNLV in Las Vegas said: “The data from this study are promising and support the use of the dose 4.5 mg /kg/day of masitinib for the future confirmatory study. Based on the mechanism of action of masitinib targeting the innate immune system via mast cells and microglia, it should be possible to investigate the correlations between clinical endpoints and biomarkers of neuro-inflammation and neurodegeneration in the next study”.
KOL BiographiesThe following key opinion leaders participated in the webcast:Bruno Dubois
Bruno Dubois is currently Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital at Paris, University Pierre et Marie Curie Paris VI. He is Director of the Behavioural Neurology Department and of the Dementia Research Center at the Hospital. He is also Director of the Research Unit Inserm U-610 of the ICM (Institut du Cerveau et de la Moelle Epinière) of the Hospital. He is coordinator of the National Reference Center on Rare Dementias and of the National Reference Center for young-onset Alzheimer patients. He is President of the Scientific Committee of France-Alzheimer and of IFRAD (International Fund Raising for Alzheimer’s disease), consultant for the Human Frontier Program and Expert of the French Agency of Drugs. He is a member of the European Alzheimer Disease Consortium (EADC). He has published on anatomical and biochemical studies on the central cholinergic systems in rodents and humans; on cognitive neuropharmacology; and on neuropsychology in patients with dementia, with special reference to memory and executive functions. He recently organized an Expert Consensus on the new criteria for Alzheimer’s disease and a Task Force on the new criteria for Parkinson’s disease dementia. He is principal or co-investigator of a number of research programs focusing on AD, prodromal AD and dementia in Parkinson’s disease.Philip Scheltens
Philip Scheltens, MD, PhD is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam, as well as Honorary Professor of Neurology at University College London. From 2011-2015, he was the scientific director of the Dutch Pearlstring Institute (PSI). In 2013, he was appointed vice-chair of the board of the Dutch “Deltaplan Dementie”. Since 2015, he has been a member of the board of the Royal Academy of Sciences and Art. His main clinical and research interests are dementia in the broadest sense, from basic research to care and translational research. He is active in the field of biomarkers and clinical trials and has been the (inter) national PI for many studies, including Phase I–III multicentre clinical trials. He is founder of, and has directed since 2000, the VUmc Alzheimer Center in The Netherlands, and during this period, he has produced over 50 PhD theses. He also founded the Alzheimer Research Center, a center dedicated to and specialised in Alzheimer clinical trials, where he is now a scientific adviser and member of the Board of Trustees. Dr. Scheltens is an active member of several societies, including the Dutch Society for Neurology, the AAN, the Alzheimer Imaging Consortium, the ISTAART Consortium, and the ECNP. He has been instrumental in organising several national and international conferences, including the Imaging Symposium attached to AAIC. He is member of the management board of the dementia panel of the EAN. He is co-editor-in-chief of Alzheimer’s Research & Therapy and acts as an ad hoc reviewer of scientific articles for all of the major journals. He has authored >730 peer reviewed papers and >50 book chapters. His current Hirsch factor is 117 (Google Scholar).Jeffrey L. Cummings
Jeffrey L. Cummings, M.D., is Director of the Chamber-Grundy Center for Transformative Neuroscience at UNLV in Las Vegas. Dr. Cummings is principal investigator/ director of the National Institutes of Health/National Institute of General Medical Sciences-funded Center for Neurodegeneration and Translational Neuroscience. Dr. Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the National Alzheimer’s Association (2008) and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. He was featured in Gentlemen’s Quarterly (June 2009) as a “Rockstar of Science.” Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases and the interface of neuroscience and society. Dr. Cummings was formerly professor of neurology and psychiatry at the University of California, Los Angeles (UCLA), director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA and director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association. Dr. Cu
https://diarynote.indered.space
コメント